TR201904638T4 - pKal aracılı rahatsızlıkların değerlendirilmesi, analizi ve tedavisi. - Google Patents
pKal aracılı rahatsızlıkların değerlendirilmesi, analizi ve tedavisi. Download PDFInfo
- Publication number
- TR201904638T4 TR201904638T4 TR2019/04638T TR201904638T TR201904638T4 TR 201904638 T4 TR201904638 T4 TR 201904638T4 TR 2019/04638 T TR2019/04638 T TR 2019/04638T TR 201904638 T TR201904638 T TR 201904638T TR 201904638 T4 TR201904638 T4 TR 201904638T4
- Authority
- TR
- Turkey
- Prior art keywords
- pkal
- mediated
- evaluation
- treatment
- analysis
- Prior art date
Links
- 230000001404 mediated effect Effects 0.000 title abstract 5
- 238000004458 analytical method Methods 0.000 title abstract 3
- 238000011156 evaluation Methods 0.000 title abstract 2
- 102000003827 Plasma Kallikrein Human genes 0.000 abstract 2
- 108090000113 Plasma Kallikrein Proteins 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000028185 Angioedema Diseases 0.000 abstract 1
- 101800004538 Bradykinin Proteins 0.000 abstract 1
- 108010080865 Factor XII Proteins 0.000 abstract 1
- 102000000429 Factor XII Human genes 0.000 abstract 1
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 abstract 1
- 102100035792 Kininogen-1 Human genes 0.000 abstract 1
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 108010053400 protease Ci Proteins 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/38—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
- C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4703—Regulators; Modulating activity
- G01N2333/4706—Regulators; Modulating activity stimulating, promoting or activating activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/81—Protease inhibitors
- G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- G01N2333/811—Serine protease (E.C. 3.4.21) inhibitors
- G01N2333/8121—Serpins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
- G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
- G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
- G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
- G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
- G01N2333/96433—Serine endopeptidases (3.4.21)
- G01N2333/96441—Serine endopeptidases (3.4.21) with definite EC number
- G01N2333/96455—Kallikrein (3.4.21.34; 3.4.21.35)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
- G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
- G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
- G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
- G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
- G01N2333/96433—Serine endopeptidases (3.4.21)
- G01N2333/96441—Serine endopeptidases (3.4.21) with definite EC number
- G01N2333/96458—Factor XII (3.4.21.38)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/70—Mechanisms involved in disease identification
Abstract
Buluş, plazma kallikrein, Faktör XII veya her ikisine bağlanan plazma proteaz CI inhibitörünün (CI-INH) saptanmasına ilişkin analiz yöntemlerini ve pKal aracılı veya bradikinin aracılık rahatsızlık riski bulunan veya bundan şikayet eden süjelerin tanımlanmasına yönelik kullanımlarını sağlar. Sağlanan yöntemler, plazma kallikrein aracılı anjiyoödem (KMA) veya pKal?nin aracılık ettiği diğer hastalıkları olan hastaların değerlendirmede ve tedavide faydalı olan analizine izin verir.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361754600P | 2013-01-20 | 2013-01-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
TR201904638T4 true TR201904638T4 (tr) | 2019-04-22 |
Family
ID=51210104
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TR2019/04638T TR201904638T4 (tr) | 2013-01-20 | 2014-01-17 | pKal aracılı rahatsızlıkların değerlendirilmesi, analizi ve tedavisi. |
Country Status (21)
Country | Link |
---|---|
US (2) | US10690670B2 (tr) |
EP (2) | EP3470837A1 (tr) |
JP (3) | JP6656926B2 (tr) |
KR (2) | KR102419640B1 (tr) |
CN (2) | CN110208533B (tr) |
AU (3) | AU2014207409B2 (tr) |
CA (1) | CA2898446A1 (tr) |
CY (1) | CY1121872T1 (tr) |
DK (1) | DK2946206T3 (tr) |
ES (1) | ES2718347T3 (tr) |
HK (1) | HK1214361A1 (tr) |
HR (1) | HRP20190528T1 (tr) |
HU (1) | HUE044285T2 (tr) |
IL (1) | IL239957B (tr) |
LT (1) | LT2946206T (tr) |
PL (1) | PL2946206T3 (tr) |
PT (1) | PT2946206T (tr) |
RS (1) | RS58635B1 (tr) |
SI (1) | SI2946206T1 (tr) |
TR (1) | TR201904638T4 (tr) |
WO (1) | WO2014113701A1 (tr) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005534647A (ja) | 2002-06-07 | 2005-11-17 | ダイアックス、コープ | 失血の予防及び軽減 |
SI2521568T1 (sl) | 2010-01-06 | 2019-01-31 | Dyax Corp. | Proteini, ki vežejo plazemski kalikrein |
CN103635489B (zh) | 2011-01-06 | 2016-04-13 | 戴埃克斯有限公司 | 血浆前激肽释放酶结合蛋白 |
PL2946206T3 (pl) | 2013-01-20 | 2019-07-31 | Dyax Corp. | Ocena, testy i leczenie zaburzeń mediowanych przez PKAL |
CA2901225C (en) * | 2013-03-08 | 2023-09-19 | Csl Behring Gmbh | Treatment and prevention of remote ischemia-reperfusion injury |
CN105051068A (zh) | 2013-03-15 | 2015-11-11 | 戴埃克斯有限公司 | 抗血浆激肽释放酶抗体 |
CN116585468A (zh) | 2014-01-21 | 2023-08-15 | 武田药品工业株式会社 | 血浆激肽释放酶结合蛋白和其在治疗遗传性血管性水肿中的用途 |
CN106459210A (zh) | 2014-03-27 | 2017-02-22 | 戴埃克斯有限公司 | 用于治疗糖尿病黄斑性水肿的组合物和方法 |
NZ733580A (en) | 2015-01-02 | 2024-02-23 | Takeda Pharmaceuticals Co | Bispecific antibodies against plasma kallikrein and factor xii |
KR20180014051A (ko) * | 2015-05-28 | 2018-02-07 | 코넬 유니버시티 | 혈관 부종 치료제로서의 아데노-관련 바이러스 매개 c1e1의 전달 |
EP3302540A4 (en) * | 2015-05-28 | 2018-08-22 | Cornell University | Adeno-associated virus mediated delivery of c1ei as a therapy for angioedema |
MX2018000714A (es) | 2015-07-21 | 2019-11-18 | Dyax Corp | Un inhibidor de anticuerpo monoclonal de factor xiia. |
EA201891388A1 (ru) | 2015-12-11 | 2018-11-30 | Дайэкс Корп. | Ингибиторы калликреина плазмы и их применение для лечения обострения наследственного ангионевротического отека |
AU2017325986B2 (en) | 2016-09-16 | 2023-12-14 | Takeda Pharmaceutical Company Limited | Metabolite biomarkers for diseases associated with the contact activation system |
US11815516B2 (en) * | 2016-09-16 | 2023-11-14 | Takeda Pharmaceutical Company Limited | Protein biomarkers for diseases associated with the contact activation system |
EP3521828A1 (en) * | 2018-01-31 | 2019-08-07 | Centogene AG | Method for the diagnosis of hereditary angioedema |
JP7457300B2 (ja) * | 2018-08-29 | 2024-03-28 | 国立大学法人 岡山大学 | 神経変性疾患の診断用ペプチドマーカー |
AU2020271846A1 (en) | 2019-04-12 | 2021-11-18 | Takeda Pharmaceutical Company Limited | Lateral flow immunoassay for measuring functional C1-esterase inhibitor (C1-INH) in plasma samples |
US11754570B2 (en) | 2019-04-16 | 2023-09-12 | Takeda Pharmaceutical Company Limited | Methods for quantitation of functional C1 esterase inhibitor (FC1-INH) |
CN115569195A (zh) * | 2021-06-21 | 2023-01-06 | 武汉大学 | 血浆激肽释放酶原在制备预防和/或治疗心脑血管疾病的药物中的用途 |
CN115725552A (zh) * | 2022-08-15 | 2023-03-03 | 西南大学 | 重组表达具有明胶酶活性p37k蛋白酶的方法及其提高p37k蛋白酶性能的方法 |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1176560A (en) | 1980-09-30 | 1984-10-23 | Peter C. Harpel | Process for determining inhibitor-enzyme complexes and composition for use therein |
US4849353A (en) * | 1980-09-30 | 1989-07-18 | Cornell Research Foundation, Inc. | Immunocapture of enzyme inhibitor, enzyme complexes and uses thereof |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
US4881175A (en) | 1986-09-02 | 1989-11-14 | Genex Corporation | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
JPH0754323B2 (ja) | 1988-10-17 | 1995-06-07 | 三洋化成工業株式会社 | 免疫測定法および免疫測定試薬 |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
ES2206447T3 (es) | 1991-06-14 | 2004-05-16 | Genentech, Inc. | Anticuerpo humanizado para heregulina. |
US6057287A (en) | 1994-01-11 | 2000-05-02 | Dyax Corp. | Kallikrein-binding "Kunitz domain" proteins and analogues thereof |
DK0739355T3 (da) | 1994-01-11 | 2005-01-24 | Dyax Corp | Kallikrein-inhiberende "Kunitz-domæne"-proteiner og analoger deraf |
CN1057607C (zh) | 1995-12-04 | 2000-10-18 | 广州市博普生物技术有限公司 | 一种双功能层析材料及制备方法和应用 |
AU6369700A (en) * | 1999-07-23 | 2001-02-13 | Coagulation Diagnostics, Incorporated | Method for measuring coagulant factor activity in whole blood |
PT1252184E (pt) | 2000-01-31 | 2008-04-15 | Pharming Intellectual Pty Bv | Inibidor humano c1 produzido no leite de mamíferos transgénicos |
US6905816B2 (en) | 2000-11-27 | 2005-06-14 | Intelligent Medical Devices, Inc. | Clinically intelligent diagnostic devices and methods |
CA2430110C (en) | 2000-11-27 | 2012-03-27 | Intelligent Medical Devices L.L.C. | Clinically intelligent diagnostic devices and methods |
US20040152633A1 (en) | 2001-05-31 | 2004-08-05 | Jorgensen Marianne Ulrich | Kunitz-type sequences and polypeptides |
KR20040089608A (ko) | 2002-02-07 | 2004-10-21 | 델타 바이오테크놀로지 리미티드 | Hiv 억제 단백질 |
JP2005534647A (ja) | 2002-06-07 | 2005-11-17 | ダイアックス、コープ | 失血の予防及び軽減 |
ES2481672T3 (es) | 2003-07-17 | 2014-07-31 | Pacific Edge Limited | Marcadores para la detección del cáncer gástrico |
WO2005098446A2 (en) | 2004-03-31 | 2005-10-20 | The Johns Hopkins University | Biomarkers for ovarian cancer |
EP1598428A1 (en) * | 2004-05-18 | 2005-11-23 | Georg Dewald | Methods and kits to detect Hereditary angioedema type III |
JP5236293B2 (ja) * | 2005-01-13 | 2013-07-17 | ブリストル−マイヤーズ スクイブ カンパニー | Xia因子阻害剤としての置換ビアリール化合物 |
WO2006091459A2 (en) * | 2005-02-24 | 2006-08-31 | Joslin Diabetes Center, Inc. | Compositions and methods for treating vascular permeability |
CA2630838A1 (en) * | 2005-11-23 | 2007-05-31 | Georg Dewald | Detection and treatment of drug associated angioedema |
US7276480B1 (en) | 2005-12-30 | 2007-10-02 | Dyax Corp. | Prevention and reduction of blood loss |
US7923240B2 (en) * | 2006-03-31 | 2011-04-12 | Intel Corporation | Photo-activated field effect transistor for bioanalyte detection |
AU2008206258B2 (en) * | 2007-01-16 | 2013-06-13 | Musc Foundation For Research Development | Compositions and methods for diagnosing, treating, and preventing prostate conditions |
US20100119512A1 (en) * | 2007-01-25 | 2010-05-13 | Joslin Diabetes Center | Methods of diagnosing, treating, and preventing increased vascular permeability |
ES2753183T3 (es) * | 2007-02-12 | 2020-04-07 | Csl Behring Gmbh | Aplicación terapéutica de inhibidores de la proteasa de serina de tipo Kazal |
US20110207155A1 (en) | 2008-10-13 | 2011-08-25 | Xeptagen Spa | Method for the preparation of immunoconjugates and use thereof |
AU2010203712A1 (en) * | 2009-01-06 | 2010-07-15 | Dyax Corp. | Treatment of mucositis with kallikrein inhibitors |
US8883153B2 (en) * | 2009-03-27 | 2014-11-11 | The Research for The State University of New York | Methods for preventing and treating angioedema |
US20110140706A1 (en) * | 2009-05-07 | 2011-06-16 | Groves John T | Particle-Based Electrostatic Sensing and Detection |
SI2521568T1 (sl) * | 2010-01-06 | 2019-01-31 | Dyax Corp. | Proteini, ki vežejo plazemski kalikrein |
CN103635489B (zh) | 2011-01-06 | 2016-04-13 | 戴埃克斯有限公司 | 血浆前激肽释放酶结合蛋白 |
PL2946206T3 (pl) | 2013-01-20 | 2019-07-31 | Dyax Corp. | Ocena, testy i leczenie zaburzeń mediowanych przez PKAL |
-
2014
- 2014-01-17 PL PL14740167T patent/PL2946206T3/pl unknown
- 2014-01-17 CA CA2898446A patent/CA2898446A1/en active Pending
- 2014-01-17 HU HUE14740167 patent/HUE044285T2/hu unknown
- 2014-01-17 PT PT14740167T patent/PT2946206T/pt unknown
- 2014-01-17 EP EP18208603.3A patent/EP3470837A1/en active Pending
- 2014-01-17 KR KR1020217002399A patent/KR102419640B1/ko active IP Right Grant
- 2014-01-17 ES ES14740167T patent/ES2718347T3/es active Active
- 2014-01-17 RS RS20190422A patent/RS58635B1/sr unknown
- 2014-01-17 DK DK14740167.3T patent/DK2946206T3/en active
- 2014-01-17 WO PCT/US2014/012090 patent/WO2014113701A1/en active Application Filing
- 2014-01-17 TR TR2019/04638T patent/TR201904638T4/tr unknown
- 2014-01-17 CN CN201910598906.0A patent/CN110208533B/zh active Active
- 2014-01-17 AU AU2014207409A patent/AU2014207409B2/en active Active
- 2014-01-17 EP EP14740167.3A patent/EP2946206B1/en active Active
- 2014-01-17 JP JP2015553859A patent/JP6656926B2/ja active Active
- 2014-01-17 LT LTEP14740167.3T patent/LT2946206T/lt unknown
- 2014-01-17 US US14/761,671 patent/US10690670B2/en active Active
- 2014-01-17 SI SI201431141T patent/SI2946206T1/sl unknown
- 2014-01-17 KR KR1020157022390A patent/KR102209796B1/ko active IP Right Grant
- 2014-01-17 CN CN201480016957.3A patent/CN105452860B/zh active Active
-
2015
- 2015-07-15 IL IL239957A patent/IL239957B/en active IP Right Grant
-
2016
- 2016-02-29 HK HK16102318.3A patent/HK1214361A1/zh unknown
-
2019
- 2019-03-18 HR HRP20190528TT patent/HRP20190528T1/hr unknown
- 2019-04-09 CY CY20191100391T patent/CY1121872T1/el unknown
-
2020
- 2020-02-05 JP JP2020018105A patent/JP7441662B2/ja active Active
- 2020-03-18 AU AU2020201946A patent/AU2020201946B2/en active Active
- 2020-05-22 US US16/881,911 patent/US11892450B2/en active Active
-
2021
- 2021-12-23 AU AU2021290331A patent/AU2021290331A1/en active Pending
-
2022
- 2022-03-31 JP JP2022059994A patent/JP2022106720A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TR201904638T4 (tr) | pKal aracılı rahatsızlıkların değerlendirilmesi, analizi ve tedavisi. | |
CY1120246T1 (el) | Ενωσεις αναστολεων μεταλλοενζυμου | |
CY1124307T1 (el) | Φαρμακευτικη συνθεση, μεθοδοι θεραπειας και χρησεις αυτων | |
CY1121360T1 (el) | Αναστολεις dna-pk | |
CY1120390T1 (el) | Συνθεση και μεθοδος για διαγνωση και θεραπεια ασθενειων που σχετιζονται με εκφυλισμο νευριτων | |
EP4234583A3 (en) | Evaluation and treatment of bradykinin-mediated disorders | |
CY1123172T1 (el) | Δοκιμασια για συλληψη και ανιχνευση κυκλοφορουντων κυτταρων πολλαπλου μυελωματος απο αιμα | |
MX2016002423A (es) | Composiciones y metodos de diagnostico para el tratamiento de glioblastoma. | |
BR112014031365A2 (pt) | métodos de detectar doenças ou condições | |
MX2014016014A (es) | Metodos para determinar eficacia de farmacos usando proteinas asociadas a cereblon. | |
CY1116719T1 (el) | Μεθοδοι ανιχνευσης αντισωματων αντι-φαρμακου | |
EA201500835A1 (ru) | Терапевтическая и диагностическая мишень для рака, включающая dll3-связывающие реагенты | |
MY163521A (en) | ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF | |
EA201391587A1 (ru) | Комбинированная терапия на основе hsp90 | |
EA201591417A1 (ru) | Новый способ диагностики депрессии и мониторинга эффективности терапии | |
EA201490778A1 (ru) | АНТИТЕЛА ПРОТИВ HtrA1 И СПОСОБЫ ПРИМЕНЕНИЯ | |
CR20160270A (es) | ANTICUERPOS ANTI-TAU (pS422) HUMANIZADOS Y MÉTODOS DE UTILIZACIÓN | |
TR201904980T4 (tr) | Bir B-Raf inhibitörü, bir EGFR inhibitörü ve isteğe bağlı olarak bir PI3K-alfa inhibitörü içeren farmasötik kombinasyonlar. | |
EA201690213A1 (ru) | Композиции и способ лечения связанных с комплементом состояний | |
TR201907261T4 (tr) | DKK-1 antikorları. | |
TR201907241T4 (tr) | IL-17 inhibitörü terapisi etkinliği için bir biyo-işaret olarak lipokalin 2. | |
EA201490948A1 (ru) | Способ определения соблюдения гигиены рук | |
EA201790211A1 (ru) | Способ прогнозирования результата лечения афлиберцептом пациента, предположительно страдающего от рака | |
PH12015500169A1 (en) | Prediction of treatment response to jak/stat inhibitor | |
MX2022010954A (es) | Dispositivo para la deteccion de proteinas mal plegadas y metodos de uso del mismo. |